The Director has the overall responsibility for the planning and operation of research at UPCI. The Associate Directors provide scientific and administrative leadership and support the Director. The Associate Directors for Basic, Clinical and Translational Research have the broad responsibilities in working with the Director of UPCI to plan the scientific directions, strengthening and expansion of existing programs, development of new programs. They also provide input in recruitment of new faculty into the programs. Through all these decisions, the focus and emphasis remain on the translational aspects of each programs and collaborative interactions between programs. Basic research occurs in all twelve CCSG programs and the Associate Directors for Basic and Translational Research are tasked with the responsibility of ensuring that the labbased research activities translate into clinical applications. The Associate Director for Clinical investigations has the critical responsibility of facilitating interdisciplinary clinical and translational research via the clinical research program. The Associate Director for Administration and Strategic Planning has the centralized role of coordinating all aspects ofthe research operations and the overall administration and management ofthe UPCI. The Associate Director for Research Services has the responsibility for oversight of all facets of the services provided by the shared facilities. Working together, the two administrative Associate Directors provide unique strength to the administrative functions ofthe cancer institute.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA047904-24S1
Application #
8519312
Study Section
Special Emphasis Panel (ZCA1-RTRB-L)
Project Start
2012-08-01
Project End
2015-07-31
Budget Start
2012-08-01
Budget End
2013-07-31
Support Year
24
Fiscal Year
2012
Total Cost
$113,625
Indirect Cost
$38,625
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Steinman, Justin; Epperly, Michael; Hou, Wen et al. (2018) Improved Total-Body Irradiation Survival by Delivery of Two Radiation Mitigators that Target Distinct Cell Death Pathways. Radiat Res 189:68-83
Yockey, Laura J; Jurado, Kellie A; Arora, Nitin et al. (2018) Type I interferons instigate fetal demise after Zika virus infection. Sci Immunol 3:
Chen, Jingci; Nagle, Alison M; Wang, Yu-Fen et al. (2018) Controlled dimerization of insulin-like growth factor-1 and insulin receptors reveals shared and distinct activities of holo and hybrid receptors. J Biol Chem 293:3700-3709
Qin, Ye; Vasilatos, Shauna N; Chen, Lin et al. (2018) Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade. Oncogene :
Diaz-Perez, Julio A; Killeen, Meaghan E; Yang, Yin et al. (2018) Extracellular ATP and IL-23 Form a Local Inflammatory Circuit Leading to the Development of a Neutrophil-Dependent Psoriasiform Dermatitis. J Invest Dermatol 138:2595-2605
Evdokimova, Viktoria N; Gandhi, Manoj; Nikitski, Alyaksandr V et al. (2018) Nuclear myosin/actin-motored contact between homologous chromosomes is initiated by ATM kinase and homology-directed repair proteins at double-strand DNA breaks to suppress chromosome rearrangements. Oncotarget 9:13612-13622
Bissel, Stephanie J; Gurnsey, Kate; Jedema, Hank P et al. (2018) Aged Chinese-origin rhesus macaques infected with SIV develop marked viremia in absence of clinical disease, inflammation or cognitive impairment. Retrovirology 15:17
Knickelbein, Kyle; Tong, Jingshan; Chen, Dongshi et al. (2018) Restoring PUMA induction overcomes KRAS-mediated resistance to anti-EGFR antibodies in colorectal cancer. Oncogene 37:4599-4610
Redner, Robert L; Beumer, Jan H; Kropf, Patricia et al. (2018) A phase-1 study of dasatinib plus all-trans retinoic acid in acute myeloid leukemia. Leuk Lymphoma 59:2595-2601
Ancevski Hunter, Katerina; Socinski, Mark A; Villaruz, Liza C (2018) PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer. Mol Diagn Ther 22:1-10

Showing the most recent 10 out of 1187 publications